{
  "docId": "019de072-e6c6-771e-b24a-5adaac3cef4b",
  "docSlug": "1c626f0801e0e9ad1e805f8e0140c291",
  "documentTitle": "Alkermes | Results Presentation Deck | 26 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 26,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The table uses checkmarks and crosses to compare clinical and molecular attributes across seven different drug candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e6c6-771e-b24a-5adaac3cef4b/23",
  "deckHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b",
  "deckJsonHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b.json",
  "deckAnchorHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Data not presented / available as of June 1, 2022; For illustrative purposes only. Not based on head-to-head studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b1f2f7a-9547-4059-bb8a-9bfc725845e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.79
      },
      "kind": "source-note",
      "text": "References 1-7 listed at the bottom.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68da0263-4620-4fe9-89bb-a5c1ac5655c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison table of Nemvaleukin vs Proleukin, Bempeg, THOR-707, MDNA-114, RG6279, and WTX-124 across 6 clinical/molecular criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffe74f08-19e8-4024-92ff-050cb5d9bae7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Nemvaleukin: Potential First-in-Class, Differentiated IL-2 Variant Immunotherapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "892bf442-8757-4d99-b620-146adbe03f41",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 21,
      "beatId": "4c209350-76ea-4ef7-8da0-7ce24752be33",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 21-26 discuss the potential impact and next steps for Nemvaleukin Alfa.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 21,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1538aa6-829a-4071-bbb6-a49e64a6fa94",
      "evidence": "Slides 21-26 discuss the potential for registration and next steps.",
      "position": 2,
      "objective": "What are the next steps for Nemvaleukin Alfa?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}